ABL1 and breast cancer: To determine the therapeutic impact of rescuing of miR-142 deficit on delaying the BC-like transformation, next we treated a cohort of miR-142−/−BCR-ABL mice with CpG-M-miR-142 (20 mg/kg/day, iv) or SCR for 4 weeks, starting on the day after BCR-ABL induction (Fig. 6d).